Share on LinkedInShare on LinkedIn

ARTICLE · 18 FEBRUARY 2022

Patent Case Summaries | Week Ending February 11, 2022

Adapt Pharma Operations Ltd., et al. v. Teva Pharmaceuticals USA, Inc., et al., No. 2020-2106 (Fed. Cir. (D.N.J.) Feb. 10, 2022). Opinion by Stoll, joined by Prost. Dissenting opinion by Newman.

United StatesIntellectual Property

A weekly summary of the precedential patent-related opinions issued by the Court of Appeals for the Federal Circuit and the opinions designated precedential or informative by the Patent Trial and Appeal Board.

Adapt Pharma Operations Ltd., et al. v. Teva Pharmaceuticals USA, Inc., et al., No. 2020-2106 (Fed. Cir. (D.N.J.) Feb. 10, 2022). Opinion by Stoll, joined by Prost. Dissenting opinion by Newman.

Adapt accused Teva of infringing four patents directed to methods of treating opioid overdose by intranasal administration of a naloxone formulation, as well as devices for intranasal administration. Teva asserted invalidity based on two different combinations of prior art. After a two-week bench trial, the district court determined that the asserted claims would have been obvious in view of the prior art. Adapt appealed.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from